Novartis to Squeeze Out MorphoSys Minority Shareholders, Initiate Delisting
Novartis to Squeeze Out MorphoSys Minority Shareholders, Initiate Delisting
諾華將強制收購morphosys的少數股東，並開始退市
MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG and Novartis AG hereinafter collectively referred to as "Novartis") also informed MorphoSys of their intention to merge MorphoSys into Novartis by initiating a squeeze-out of MorphoSys' minority shareholders.
2024年5月，MorphoSys AG(股票代碼: MOR)與Novartis BidCo AG和諾華製藥達成退市協議，經成功完成收購。Novartis BidCo Germany AG(下稱“Novartis”，與Novartis BidCo AG和諾華製藥一起)還通知了MorphoSys他們將通過擠出少數股東的方式將MorphoSys合併至Novartis。
In April 2024, Novartis submitted a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares, offering MorphoSys shareholders € 68.00 per share in cash...
2024年4月，諾華製藥以68歐元的現金價(收購要...
登入免費觀看全文
登入/註冊